• Twitter Social Icon
  • LinkedIn Social Icon

AMP-DHL biopharma investor intellectual property issues blog 

See our blog on select current IP issues relevant to biopharma investors created by ollaborative efforts of our Amp biopharma investment team and our Double Helix Law (DHL) biotech patent legal team.


November 30, 2018

Download Full Article


  • Amarin has patent protection for Vascepa® out to 2030, including protection related to the possible expanded Reduce-It trial label.

  • Two U.S. formulation patents and 22 U.S. Vascepa® Patents expire between 1/27/20 and 4/29/30, with 2...

Please reload


Contact Us

Interested and want to learn more? Send us a note below. 

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services, including our Amp Core™ product, are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action. 

By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here.

Amp Core™ is a trademark of Amp Biotech Research, LLC

©2019 BY Amp Biotech Research